Curcumin, the active compound in turmeric, has garnered significant attention for its potential anticancer properties. AE17 is a turmeric supplement enhanced with Micelle Technology, designed to improve the bioavailability of curcumin, making it more effective in the body.
Research has shown that curcumin can inhibit the formation of tumors and induce apoptosis (programmed cell death) in cancer cells. A study published in PubMed highlights curcumin’s role in cancer prevention and therapy, noting its antioxidant and pro-oxidant properties that contribute to its anticancer effects. Read more here.
In Episode 44 of ‘Critically Thinking with Dr. T and Dr. P’, experts discuss various aspects of cancer and alternative therapies. The episode provides valuable context on the broader conversation around cancer treatments. Watch the episode here.
Studies have demonstrated curcumin’s potential in cancer prevention and therapy. One study published on PubMed (DOI: 20924967) discusses how curcumin can inhibit the growth of cancer cells and improve outcomes for those undergoing cancer treatment. Read more here.
Another study explores how curcumin plays a role in inducing apoptosis in cancer cells, further validating its anticancer effects. This study can be accessed through PubMed here.
A third study elaborates on curcumin’s ability to modulate multiple signaling pathways involved in the development and progression of cancer, providing insight into how it works within the body. More information on this can be found in this PubMed study.
AE17 is a turmeric supplement that utilizes Micelle Technology to enhance the absorption of curcumin. This formulation aims to deliver the therapeutic benefits of turmeric more effectively. The supplement is available for purchase through Theon Global. Learn more and purchase AE17.